Group B streptococcus type II and type V polysaccharide-protein

Details Group B streptococcus type II and type V polysaccharide-protein Group B streptococcus type II and type V polysaccharide-protein

1998-02-13

1999-11-30

Chin, Christopher L.

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

4242031, 4241931, 42419711, 530403, 530813, 530825, A61K 3909

Patent

active

059938250

ABSTRACT:
This invention relates to antigenic conjugate molecules comprising the capsular polysaccharide of Group B streptococcus type II which are covalently linked to protein. This invention further relates to antigenic conjugate molecules comprising the capsular polysaccharide of Group B streptococcus type V which are covalently linked to protein. This invention also relates to vaccines and methods of immunizing mammals, including humans against infection by Group B streptococcus type II (GBS II) and/or Group B streptococcus type V (GBS V). Multivalent vaccines comprising the conjugate molecules of this invention and antigens to other pathogenic bacteria are also claimed.

REFERENCES:
patent: 4207414 (1980-06-01), Kasper
patent: 4284537 (1981-08-01), Beachley
patent: 4324887 (1982-04-01), Kasper
patent: 4356170 (1982-10-01), Jennings et al.
patent: 4356263 (1982-10-01), Jennings et al.
patent: 4367221 (1983-01-01), Kasper
patent: 4367222 (1983-01-01), Kasper
patent: 4367223 (1983-01-01), Kasper
patent: 4425330 (1984-01-01), Norcross et al.
patent: 4438261 (1984-03-01), Barnett
patent: 4619828 (1986-10-01), Gordon
patent: 4757134 (1988-07-01), Blake et al.
patent: 4789735 (1988-12-01), Frank et al.
patent: 4902506 (1990-02-01), Anderson et al.
patent: 5302386 (1994-04-01), Kasper
Abstract of Grant No. 5R01AI30628-02, "Prevention of perinatal group B streptococcal infections (human, mice, rabbits)", Kasper D.L., Principal Investigator, Dialog File 265/266, Fed. Research in Progress, printout of Jan. 26, 1993 for fiscal year 1992.
Abstract of Grant No. 2R37A23339-08, "Immunochemistry of Group B Streptococcus polysaccharides (human, mice, rabbits)", Kasper, D.L., Principal Investigator, Dialog File 265/266, Fed. Research in Progress, printout of Jan. 26, 1993 for fiscal year 1992.
Attachment A (Work Statement) form Request for Proposal No. NIH-NIAID-DMID-92-13, issued by the Department of Health and Human Services for the National Institutes of Health on Jan. 21, 1992, entitled, "Prevention of Group B Streptococcal Infections in Neonatal and Infant Populations".
Baker et al., New Engl. J. Med., 319 18:1180-1185, 1988.
Baker et al., Reviews of Infectious Diseases 7(4):458-467, 1985.
Baker, C.J., "Immunization to Prevent Group B Streptococcal Disease: Victories and Vexations", Journal of Infectious Disease, vol. 161, No. 5, pp. 917-921, May 1990.
Bittle, J.L., et al. "Vaccines Produced by Conventional Means to Control Major Infectious Diseases of Man and Animals", Adv. Vet. Sci. Comp. Med., vol. 33, pp. 1-63, Feb. 1989.
Boyer et al., Clinical Research 34(4):962A, 1986.
Coleman, R.T., et al. "Prevention of Neonatal Group B Streptococcal Infections: Advances in Maternal Vaccine Development", Obst. Gynec., vol. 80, No. 2, pp. 301-309, Aug. 1992.
Devi, et al. "Antibodies to poly[(2.fwdarw.8)-.alpha.-N-acetylneuraminic acid] and poly[2.fwdarw.9)-.alpha.-N-acetylneuraminic acid] are elicited by immunization of mice with Escherichia coli K92 conjugates: potential vaccines for groups B and C meningococci and E. coli K1", Proc. Natl. Acad. Sci. USA, vol. 88, Aug. 1991, pp. 7175-7179.
Dick and Beurret (1989) "Glyconjugates of Bacterial Carbohydrate Antigens--A Survey and Consideration of Design and Preparation Factors" Conjugate Vaccines) In Contrib. Microbiol. Immunol. (Cruse, JM and Lewis, RE. Tr. (eds.) Basel Karger Vol. 10:48:114.
Dintzis, "Rational Design of Conjugate Vaccines", Pediatric Research, vol. 32, No. 4, pp. 376-385, Oct. 1992.
Facklam et al., "Streptucocci and Aerocucci" in Manual of Clinical Microbiology, Lenette et al. eds. American Society for Microbiol. Wash., D.C. 1985, p. 154-175.
Feldman, et al. "The immune response to the group B streptococcus", Reviews in Medical Microbiology, vol. 3, No. 1, Jan. 1992, pp. 52-58.
Givner, et al. "Pooled Human IgH hyperimmune for type III Group B Streptococci: Evaluation against multiple strains in vitro and in experimental diseases", J. Infectious Diseases, vol. 163, pp. 1141-1145, May 1991.
Heiman, et al. "The Opsonic Antibody Response of Female Rats to Type III Group B Streptococcal Immunization: a Model for Maternal Immunity", Veterinary Immunology and Immunopathy, vol. 24, 1990, pp. 79-89.
Insel, R.A., "Maternal Immunization of Prevent Neonatal Infections", New England Journal of Medicine, vol. 319, No. 18, pp. 1219-1220, Nov. 1988.
Jennings and Lugowski, "Immunochemistry of Groups A, B and C Meningococcal Polysaccharide Tetanus Toxoid Conjugates", The Journal of Immunology, 127:1011-1017 (1981).
Jennings, (1983) "Capsular Polysaccharrides as Human Vaccines" In Advances Carbohydrate Chemistry and Biochemistry, vol. 41:155-207. Academic Press, Inc., NY, NY.
Jennings, et al. (1982) "Structural Determination of the Capsular Polysaccharide Antigen of Type II Group B Streptococcus", The Journal of Biological Chemistry, vol. 258:1793-1798.
Jennings, et al., Biochemistry, 20(16):4511-4518, 1981.
Kasper, et al. (1983) "Immunochemical Analysis and Immunogenicity of the Type II Group B Streptococcal Capsular Polysaccharide", J. Clin. Invest. vol. 72:260-269.
Lagergard, et al., "Synthesis and Immunological Properties of Conjugates Composed of Group B Streptococcus Type III Capsular Polysaccharide Covalently Bound to Tetanus Toxoid", Infection and Immunity, Mar. 1990, vol. 58, No. 3, pp. 687-694.
Lerner, R.A., et al. "The Development of Synthetic Vaccines", The Biology of Immunologic Disease, Dixon, F.J., et al., eds., Sinauer Associates: Sunderland, MA, pp. 331-338, 1983.
Madoff, et al. "Maternal Immunization of Mice with Group B Streptococcal Type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple stereotypes", J. Clin. Invest., vol. 94, pp. 286-292, Jul. 1994.
Madoff, L.C., et al. "Protection of Neonatal Mice from Group B Streptococcal Infection by Maternal Immunization with Beta C Protein", Infect. Immun., vol. 60, No. 12, pp. 4989-4994, Dec. 1992.
Paoletti (1992) "Effects of Chain Length on the Immunogenicity in Rabbits of Group B Streptococcus Type III Oligosaccharride--Tetanus Toxoid Conjugate", J. Clin. Invest. 89:203-209.
Paoletti (1992) "Group B Streptoccus Type II Polysaccharride--Tetanus Toxoid Conjugate Vaccine" Infection and Immunity, vol. 60:4009-4014.
Paoletti, L.C., et al. "Group B Streptococcus Type III Glycoconjugate Vaccines", Trends in Glycosci. Glycotech., vol. 4, No. 17, pp. 269-278, May 1992.
Paoletti, et al., "Immunogenicity of Group B Streptococcus Type III Polysaccharide-tetanus Vaccine in Baboons", Infection and Immunity, vol. 64, No. 2, pp. 677-679, Feb. 1996.
Paoletti, et al. (1990) "An Oligosaccharide-Tetanus Toxoid Conjugate Vaccine against Type III Group B Streptococcus", The Journal of Biological Chemsitry, vol. 265:18278-18283.
Pappenheimer, et al. (1972) "An Immunological Study of the Diptheria Toxin Molecule", Immunochemistry, vol. 9, pp. 891-906.
Reuter et al., Glycoconjugate J. 6:35-44, 1989.
Rodewald, et al. (1992) "Neonatal Mouse Model of Group B Streptococcal Infection", The Journal of Infectious Diseases, vol. 166:635-9.
Roy, et al. "Efficient Synthesis of .alpha.(2-8)-Linked N-Acetyl and N-Glycolylyneuraminic Acid Disaccharides from Colominic Acid", Journal of Glycoconjugate, vol. 7, 1990, pp. 3-12.
Ward et al., "Haemophilus Influenza Vaccines" in Vaccines, Plotkin et al eds. W.B. Saunders Co., Philadelphia, 1988 p. 300-330.
Wessels, et al., "Immunogenicity and Protective Activity in Animals of a Type V Group B Streptococcal Polysaccharide-Tetanus Toxoid Conjugate Vaccine", The Journal of Infectious Diseases, vol. 171, 1995, pp. 879-884.
Wessels, et al. "Structure and Immunochemistry of an Oligosaccharide Repeating Unit of the Capsular Polysaccharide of Type III Group B Streptococcus", The Journal of Biological Chemistry, vol. 262, No. 17, Jun. 15, 1987, pp. 8262-8267.
Wessels et al., J. Biol. Chem. 266(11): 6714-6719, 1991.
Wessels, et al., (1989) "Isolation and Characterization of Type IV Group B Streptococcus Capsular Polysaccharide" Infection and Immunity vol. 57, No. 4:1089-1904.
Wessels, et al., J. Clin. Invest. 86:1428-1433, 1990.
Wilkinson, H.W., et al. "Type-Specifi

Affiliated with

Also associated with

Rating

Group B streptococcus type II and type V polysaccharide-protein does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Group B streptococcus type II and type V polysaccharide-protein , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Group B streptococcus type II and type V polysaccharide-protein will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1668197